TOP TEN perturbations for 1553415_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1553415_at
Selected probe(set): 1553415_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1553415_at (1553415_at) across 6672 perturbations tested by GENEVESTIGATOR:

Crohn's disease study 3 (baseline; non-responder; ileum) / normal ileum mucosa tissue

Relative Expression (log2-ratio):-4.225589
Number of Samples:10 / 6
Experimental Crohn's disease study 3 (baseline; non-responder; ileum)
Ileal mucosal biopsies derived from Crohn's disease patients who are non-responders to infliximab treatment. Biopsies were taken within a week prior to the first intravenous infusion of infliximab; the response to infliximab was assessed 4 to 6 weeks after the first infliximab treatment. The response was defined as a complete mucosal healing with a decrease of at least 3 points on the histological score for Crohn's disease (CDc) and as a decrease to a Mayo endoscopic subscore of 0 or 1 with a decrease to grade 0 or 1 on the histological score for ulcerative colitis (UC). More strict response criteria were used for Crohn's ileitis (CDi). More baseline information about the patients are available in the publication.
Control normal ileum mucosa tissue
Ileal mucosal biopsy from control subject obtained at the endoscopy for polyps screening.

Crohn's disease study 3 (baseline; responder; ileum) / normal ileum mucosa tissue

Relative Expression (log2-ratio):-2.3854809
Number of Samples:8 / 6
Experimental Crohn's disease study 3 (baseline; responder; ileum)
Ileal mucosal biopsy derived from Crohn's disease patients who are responders to infliximab treatment. Biopsies were taken within a week prior to the first intravenous infusion of infliximab; the response to infliximab was assessed 4 to 6 weeks after the first infliximab treatment. The response was defined as a complete mucosal healing with a decrease of at least 3 points on the histological score for Crohn's disease (CDc) and as a decrease to a Mayo endoscopic subscore of 0 or 1 with a decrease to grade 0 or 1 on the histological score for ulcerative colitis (UC). More strict response criteria were used for Crohn's ileitis (CDi). More baseline information about the patients are available in the publication.
Control normal ileum mucosa tissue
Ileal mucosal biopsy from control subject obtained at the endoscopy for polyps screening.

Crohn's disease study 3 (baseline; responder; ileum) / Crohn's disease study 3 (baseline; non-responder; ileum)

Relative Expression (log2-ratio):1.8401079
Number of Samples:8 / 10
Experimental Crohn's disease study 3 (baseline; responder; ileum)
Ileal mucosal biopsy derived from Crohn's disease patients who are responders to infliximab treatment. Biopsies were taken within a week prior to the first intravenous infusion of infliximab; the response to infliximab was assessed 4 to 6 weeks after the first infliximab treatment. The response was defined as a complete mucosal healing with a decrease of at least 3 points on the histological score for Crohn's disease (CDc) and as a decrease to a Mayo endoscopic subscore of 0 or 1 with a decrease to grade 0 or 1 on the histological score for ulcerative colitis (UC). More strict response criteria were used for Crohn's ileitis (CDi). More baseline information about the patients are available in the publication.
Control Crohn's disease study 3 (baseline; non-responder; ileum)
Ileal mucosal biopsies derived from Crohn's disease patients who are non-responders to infliximab treatment. Biopsies were taken within a week prior to the first intravenous infusion of infliximab; the response to infliximab was assessed 4 to 6 weeks after the first infliximab treatment. The response was defined as a complete mucosal healing with a decrease of at least 3 points on the histological score for Crohn's disease (CDc) and as a decrease to a Mayo endoscopic subscore of 0 or 1 with a decrease to grade 0 or 1 on the histological score for ulcerative colitis (UC). More strict response criteria were used for Crohn's ileitis (CDi). More baseline information about the patients are available in the publication.

gonadotroph adenoma study 1 / normal pituitary gland tissue

Relative Expression (log2-ratio):1.5557213
Number of Samples:7 / 8
Experimental gonadotroph adenoma study 1
Gonadotroph adenoma biopsy samples recovered during transsphenoidal surgery. The tumors were defined as demonstrating positive immunostaining for FSH, LH, or alpha subunit in greater than 5-10% of cells. Samples were scanned between 04/6/2004 - 15/4/2005.
Control normal pituitary gland tissue
Biopsy samples of healthy pituitary gland recovered post-mortem during autopsy within 2-18 hours of death. Cause of death were mostly various pulmonary or cardiovascular conditions.

colorectal adenoma study 7 (colonic crypt) / normal colonic crypt epithelial cell sample

Relative Expression (log2-ratio):-1.4784031
Number of Samples:5 / 5
Experimental colorectal adenoma study 7 (colonic crypt)
Colonic crypt epithelial cell samples obtained by laser capture microdissection (LCM) from patients with colorectal adenoma.
Control normal colonic crypt epithelial cell sample
Histopathological normal colonic crypt epithelial cells obtained by laser capture microdissection (LCM) from the distant normal colon of patients with colorectal cancer.

colorectal cancer study 33 (carcinoma; colonic mucosa) / normal colon mucosa sample

Relative Expression (log2-ratio):-1.4354692
Number of Samples:5 / 5
Experimental colorectal cancer study 33 (carcinoma; colonic mucosa)
Colonic mucosa samples obtained by laser capture microdissection (LCM) from patients with colorectal carcinoma.
Control normal colon mucosa sample
Histopathological normal colon mucosa sample obtained by laser capture microdissection (LCM) from the distant normal colon of patients with colorectal cancer.

colorectal adenoma study 7 (colonic mucosa) / normal colon mucosa sample

Relative Expression (log2-ratio):-1.4246225
Number of Samples:5 / 5
Experimental colorectal adenoma study 7 (colonic mucosa)
Colonic mucosa samples obtained by laser capture microdissection (LCM) from patients with colorectal adenoma.
Control normal colon mucosa sample
Histopathological normal colon mucosa sample obtained by laser capture microdissection (LCM) from the distant normal colon of patients with colorectal cancer.

valproic acid study 26 (2000uM) / vehicle (PBS) treated HepG2 sample

Relative Expression (log2-ratio):1.4103522
Number of Samples:3 / 12
Experimental valproic acid study 26 (2000uM)
HepG2 cells treated with compound: valproic acid (2000uM; CAS no.:99-66-1) for 24 hours. Valproic acid is hepatotoxic and may cause steatosis. HepG2 cells were treated with the IC20 concentration measured after 24 hours. ATC code:
Control vehicle (PBS) treated HepG2 sample
HepG2 cells treated with PBS (0.5% v/v) as solvent control for 24 hours.

colorectal cancer study 33 (carcinoma; colonic crypt) / normal colonic crypt epithelial cell sample

Relative Expression (log2-ratio):-1.3698964
Number of Samples:5 / 5
Experimental colorectal cancer study 33 (carcinoma; colonic crypt)
Colonic crypt epithelial cell samples obtained by laser capture microdissection (LCM) from patients with colorectal carcinoma.
Control normal colonic crypt epithelial cell sample
Histopathological normal colonic crypt epithelial cells obtained by laser capture microdissection (LCM) from the distant normal colon of patients with colorectal cancer.

null cell adenoma study 1 / normal pituitary gland tissue

Relative Expression (log2-ratio):1.1295319
Number of Samples:2 / 8
Experimental null cell adenoma study 1
Null cell adenoma biopsy samples recovered during transsphenoidal surgery. The tumors were defined by gonadotropic staining for FSH, LH, or alpha subunit in less than 5-10% of cells. Samples were scanned between 04/6/2004 - 15/4/2005.
Control normal pituitary gland tissue
Biopsy samples of healthy pituitary gland recovered post-mortem during autopsy within 2-18 hours of death. Cause of death were mostly various pulmonary or cardiovascular conditions.